Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (19920)	5/7/1998 3:36:00 PM
From: squetch	Respond to of 32384

Fugazi, It will be interesting to see what is presented at ASCO for Tamoxifen. There seems to be conflicting studies. squetch >>Women who had received Tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not....Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention...Endometrial cancers diagnosed in women treated w/ tamoxifen have poorer prognosis...<< Iatrogenic Risks of Endometrial Carcinoma After Treatment for Breast Cancer in a Large French Case-Control Study Int' J Cancer:76, 325-330 by Mignotte et al